Canadian pharmaceutical industry alarmed after Trump threatens 200% tariff on drug imports

National Post

3 days ago

WASHINGTON — Canada likely isn't the main target of U.S. President Donald Trump's threat to impose a 200 per cent tariff on pharmaceutical imports, an industry representative said Wednesday — but his plan could still put parts of the Canadian sector in peril.
Article content
'Canada is not the target but we could get caught in the crossfire if there are broad-based tariffs on pharmaceuticals,' said Canadian Generic Pharmaceutical Association president Jim Keon.
Article content
Article content
On Tuesday, Trump floated the idea of massive pharmaceutical tariffs but said he would give drug makers up to a year and a half before introducing the duties.
Article content
Article content
Trump launched an investigation under Section 232 of the Trade Expansion Act of 1962 into pharmaceuticals in April, claiming national security concerns linked to America's reliance on imported drugs. A lot of those imported drugs come from China and India.
Article content
A report on that investigation has not been released but Commerce Secretary Howard Lutnick told CNBC Tuesday that details about pharmaceutical duties would come out at the end of the month.
Article content
Generic medicines are used to fill about 90 per cent of all prescriptions in the United States. Canadian exports amount to less than five per cent of all generic medicines sold in the U.S., Keon said.
Article content
Such a low volume shouldn't trigger any U.S. concerns about an overreliance on imports, Keon said.
Article content
He said there is hope that the economic and security agreement being negotiated between Canada and the United States will ensure pharmaceuticals remain tariff-free. Ottawa and the Trump administration have set a July 21 target to finalize the deal.
Article content
Article content
'We have learned over the last six to eight months not to overreact to the statements and wait and see what actually comes out in the executive order in the tariffs themselves,' Keon said.
Article content
Article content
But if Canada is not spared from the looming pharmaceutical duties, Keon said, that would have impacts for Canadian and foreign companies that manufacture drugs in this country.
Article content
Generic pharmaceuticals have a low profit margin. Without access to the American market, Keon said, it might not be practical for some companies in Canada to continue producing certain generic medicines for the domestic market.
Article content
'I think as a Canadian industry and as part of a global industry, we've been operating without tariffs for the last several decades and imposing tariffs is going to increase costs and complicate supply chains,' Keon said.